This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Edwards Lifesciences will fight US FTC complaint, expects determination end of Q1 2026

( August 6, 2025, 19:05 GMT | Official Statement) -- MLex Summary: Edwards Lifesciences said it intends to continue to pursue regulatory approval for its proposed acquisition of JenaValve Technology and estimates a final determination by the end of the first quarter of 2026. Edwards said that blocking the merger will "limit the availability of an important treatment option for patients suffering from aortic regurgitation. The company further believes the acquisition of JenaValve will accelerate the availability, adoption and continued innovation of a life-saving treatment for patients suffering from AR." Statement follows in full. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login